Protalix Biotherapeutics (PLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2017 | 03-2017 | 12-2016 | 09-2016 | 06-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -58,698 | -59,148 | -29,365 | -26,741 | -19,451 |
| Depreciation Amortization | 2,127 | 1,082 | 2,551 | 1,822 | 1,227 |
| Accounts receivable | -3,538 | -3,092 | -1,133 | -1,358 | -4,952 |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | 367 | N/A |
| Other Working Capital | 1,095 | -1,509 | 1,124 | -378 | -4,109 |
| Other Operating Activity | 41,969 | 54,241 | -5,275 | 1,528 | 5,968 |
| Operating Cash Flow | $-17,045 | $-8,426 | $-32,098 | $-24,760 | $-21,317 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -343 | -23 | -106 | N/A | N/A |
| PPE Investments | -543 | -220 | -829 | -732 | -575 |
| Other Investing Activity | -83 | -40 | -32 | 7 | -84 |
| Investing Cash Flow | $-969 | $-283 | $-967 | $-725 | $-659 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 19,681 | N/A | N/A |
| Debt Repayment | -10,961 | -6,726 | N/A | N/A | N/A |
| Common Stock Issued | N/A | N/A | 14 | N/A | N/A |
| Financing Cash Flow | $-10,961 | $-6,726 | $19,695 | $N/A | $N/A |
| Exchange Rate Effect | 227 | 171 | 277 | 431 | 228 |
| Beginning Cash Position | 63,281 | 63,281 | 76,374 | 76,374 | 76,374 |
| End Cash Position | 34,533 | 48,017 | 63,281 | 51,320 | 54,626 |
| Net Cash Flow | $-28,748 | $-15,264 | $-13,093 | $-25,054 | $-21,748 |
| Free Cash Flow | |||||
| Operating Cash Flow | -17,045 | -8,426 | -32,098 | -24,760 | -21,317 |
| Capital Expenditure | -543 | -220 | -849 | -732 | -575 |
| Free Cash Flow | -17,588 | -8,646 | -32,947 | -25,492 | -21,892 |